Zevra Therapeutics, Inc. (ZVRA) Misses Q4 EPS by 27c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q4 EPS of ($0.67), $0.27 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $12 million versus the consensus estimate of $8.52 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Rex American Resources Corp. (REX) Tops Q2 EPS by 64c
• Uber To Cut 3,300 Jobs In Overhaul To Reduce Management Layers - Bloomberg